BR112021023054A2 - Formas cristalinas de um inibidor de btk - Google Patents

Formas cristalinas de um inibidor de btk

Info

Publication number
BR112021023054A2
BR112021023054A2 BR112021023054A BR112021023054A BR112021023054A2 BR 112021023054 A2 BR112021023054 A2 BR 112021023054A2 BR 112021023054 A BR112021023054 A BR 112021023054A BR 112021023054 A BR112021023054 A BR 112021023054A BR 112021023054 A2 BR112021023054 A2 BR 112021023054A2
Authority
BR
Brazil
Prior art keywords
crystalline forms
btk inhibitor
disorders
diseases
btk
Prior art date
Application number
BR112021023054A
Other languages
English (en)
Inventor
Andreas Kordikowski
Daniela Angst
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112021023054A2 publication Critical patent/BR112021023054A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

formas cristalinas de um inibidor de btk. a presente invenção refere-se a várias formas cristalinas anidras n-(3-(6-amino-5-(2-(n-metilacrilamido)etóxi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciclopropil-2-fluorobenzamida, assim como composições, método de fabricação e métodos de uso das mesmas. essas formas cristalinas são úteis no tratamento de doenças e distúrbios que são tipicamente amenizados pela inibição de btk. tais doenças e distúrbios podem incluir distúrbios inflamatórios e autoimunes e inflamação pulmonar e do trato respiratório.
BR112021023054A 2019-05-23 2020-05-20 Formas cristalinas de um inibidor de btk BR112021023054A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851986P 2019-05-23 2019-05-23
PCT/IB2020/054752 WO2020234779A1 (en) 2019-05-23 2020-05-20 Crystalline forms of a btk inhibitor

Publications (1)

Publication Number Publication Date
BR112021023054A2 true BR112021023054A2 (pt) 2022-03-29

Family

ID=70918748

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023054A BR112021023054A2 (pt) 2019-05-23 2020-05-20 Formas cristalinas de um inibidor de btk

Country Status (13)

Country Link
EP (1) EP3972960A1 (pt)
JP (1) JP2022534216A (pt)
KR (1) KR20220012280A (pt)
CN (1) CN113840821A (pt)
AR (1) AR118981A1 (pt)
AU (1) AU2020279927A1 (pt)
BR (1) BR112021023054A2 (pt)
CA (1) CA3137790A1 (pt)
CL (1) CL2021003057A1 (pt)
IL (1) IL287668A (pt)
MX (1) MX2021014157A (pt)
TW (1) TW202110811A (pt)
WO (1) WO2020234779A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022033569A1 (zh) * 2020-08-14 2022-02-17 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
WO2022162513A1 (en) 2021-01-26 2022-08-04 Novartis Ag Pharmaceutical composition
CA3229887A1 (en) 2021-09-03 2023-03-09 Novartis Ag Lou064 for treating multiple sclerosis
JP2024504267A (ja) 2021-12-14 2024-01-31 ノバルティス アーゲー Ｌｏｕ０６４を使用した治療の方法
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
WO2024069507A1 (en) 2022-09-30 2024-04-04 Novartis Ag Synthesis methods and intermediates for the production of remibrutinib
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1337527B1 (en) 2000-11-07 2009-10-14 Novartis AG Indolylmaleimide derivatives as protein kinase c inhibitors
TWI324064B (en) 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
NZ540427A (en) 2002-12-09 2008-04-30 Univ Texas Methods for selectively inhibiting janus tyrosine kinase 3 (Jak3)
MXPA05012461A (es) 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresores.
BRPI0506817A (pt) 2004-01-12 2007-05-29 Cytopia Res Pty Ltd inibidores seletivos de quinase
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
EP3972960A1 (en) 2022-03-30
CL2021003057A1 (es) 2022-09-09
WO2020234779A1 (en) 2020-11-26
AR118981A1 (es) 2021-11-17
CN113840821A (zh) 2021-12-24
IL287668A (en) 2021-12-01
MX2021014157A (es) 2022-01-04
JP2022534216A (ja) 2022-07-28
KR20220012280A (ko) 2022-02-03
TW202110811A (zh) 2021-03-16
CA3137790A1 (en) 2020-11-26
AU2020279927A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
BR112021023054A2 (pt) Formas cristalinas de um inibidor de btk
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
PH12021550310A1 (en) Novel sulfonamideurea compounds
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
BR112018005454A2 (pt) administração de potencializadores de cftr deuterados
EA202091709A1 (ru) Ингибиторы днк-пк
CY1116057T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
NO20063196L (no) Nye fusjonerte pyrrolokarbazoler
IS8175A (is) Píperasín afleiður og aðferðir við notkun þeirra
GEP20186885B (en) Novel compounds
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
EA202091708A1 (ru) Ингибиторы днк-пк
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
EA202192925A1 (ru) Твердые формы ингибитора glyt1
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы